Literature DB >> 7074627

Deoxycytidine and deoxythymidine kinase activities in plasma of mice and patients with neoplastic disease.

W Kreis, Z Arlin, A Yagoda, B R Leyland-Jones, L Fiori.   

Abstract

In C57BL x DBA/2 F1 (hereafter called BD2F1) mice inoculated with P815 neoplasms and in AKR mice with spontaneously developing leukemia, significant amounts of plasma deoxycytidine and thymidine kinase activities were detected in advanced disease. Undetectable or low levels of such kinase activities were observed in normal BD2F1 and in control AKR mice. Initial studies with leukemia patients revealed increased amounts of plasma deoxycytidine and thymidine kinase activities correlating favorably with the peripheral white blood cell counts. Initial studies with small numbers of patients with solid tumors revealed significant activities of both kinases in plasma of patients with four different cancers. Healthy volunteers revealed enzyme activities only insignificantly above background.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7074627

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  7 in total

1.  Serum thymidine kinase levels in cancer patients.

Authors:  K L O'Neill; W P Abram; P G McKenna
Journal:  Ir J Med Sci       Date:  1986-08       Impact factor: 1.568

2.  Elevated serum thymidine kinase activity in patients with acute viral hepatitis.

Authors:  K Tanaka; T Sishido; M Morimoto; S Inoue; Y Takamura; M Masumura
Journal:  Gastroenterol Jpn       Date:  1993-02

3.  Comparison of plasma and tissue thymidine kinase activities.

Authors:  R J Calvert; S Satchithanandam
Journal:  Br J Cancer       Date:  1989-04       Impact factor: 7.640

4.  Serum thymidine kinase in acute leukaemia.

Authors:  H Hagberg; S Gronowitz; A Killander; C Källander; B Simonsson; C Sundström; G Oberg
Journal:  Br J Cancer       Date:  1984-04       Impact factor: 7.640

5.  Thymidine kinase in breast cancer.

Authors:  J F Robertson; K L O'Neill; M W Thomas; P G McKenna; R W Blamey
Journal:  Br J Cancer       Date:  1990-10       Impact factor: 7.640

6.  The use of serum deoxythymidine kinase as a prognostic marker, and in the monitoring of patients with non-Hodgkin's lymphoma.

Authors:  J S Gronowitz; H Hagberg; C F Källander; B Simonsson
Journal:  Br J Cancer       Date:  1983-04       Impact factor: 7.640

7.  Thymidine kinase activities in mononuclear leukocytes and serum from breast cancer patients.

Authors:  P G McKenna; K L O'Neill; W P Abram; B M Hannigan
Journal:  Br J Cancer       Date:  1988-06       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.